Oral estramustine and oral etoposide for hormone-refractory prostate cancer

Urology

Volumn 50, Issue 5, 1997, Pages 754-758

  Dimopoulos, Meletios A ^a   Panopoulos, Christos ^a   Bamia, Christina ^a   Deliveliotis, Charalambos ^a   Alivizatos, Gerasimos ^a   Pantazopoulos, Dimitrios ^a   Constantinidis, Constantinos ^a   Kostakopoulos, Athanasios ^a   Kastriotis, Ioannis ^a   Zervas, Anastasios ^a   Aravantinos, Gerasimos ^a   Dimopoulos, Constantinos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRAMUSTINE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0030711034     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00323-3     Document Type: Article

References (17)

1. Eisenberger MA, and Abrams JS: Chemotherapy for prostatic carcinoma. Semin Urol 6: 303-310, 1988.
2. Yagoda A, and Petrylak D: Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 71(suppl): 1098-1109, 1993.
3. Raghavan D: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371-389, 1988.
4. Scher HI, and Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11: 1566-1572, 1993.
5. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, and Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992.
6. Sella A, Kilbourn R, Amato R, Bui C, Zokiwski AA, Ellerhorst J, and Logothetis CJ: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683-688, 1994.
7. Pienta KJ, and Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149: 1622-1625, 1993.
8. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, and Flaherty LE: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994.
9. Kaplan EL, and Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-461, 1958.
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
11. Pienta KJ: Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer. J Clin Oncol 13: 797, 1995.
12. Yagoda A, Smith JR, Soloway MS, Tomera K, Seidmon EJ, Olsson C, and Wajsman Z: Phase II study of estramustine phosphate in advanced hormone refractory prostate cancer with increasing prostate specific antigen levels (abstract). J Urol 145: 384A, 1991.
13. Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, and Sylvester R: Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the EORTC, genitourinary group prospective randomized Phase III study. J Urol 150: 1840-1844, 1993.
14. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Morgensen P, Mommen S, and Rosenkilde P: Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol 157: 929-934, 1997.
15. Hussain MH, Pienta KJ, Redman BG, Cummings GD, and Flaherty LE: Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 74: 100-103, 1994.
16. Kelly WK, Scher HI, Mazumbar M, Vlamis V, Schwartz M, and Fossa SD: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615, 1993.
17. Seidman A, Scher H, Petrylak D, Dershaw DD, and Curley T: Estramustine and vinblastine: use of PSA as a clinical trial end-point for hormone refractory prostate cancer. J Urol 147: 931-934, 1992.